Physician profile
Andrew Maxwell
NPI 1891435988
$680.05
in general payments reported to CMS, 2019-2025
10 companies · $673 in 2025
The $673 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $7.42 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $270.66 | 2025 | Austedo Xr, Uzedy |
| Alkermes, INC. | $93.10 | 2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $82.27 | 2025 | |
| Vanda Pharmaceuticals INC. | $68.92 | 2025 | Fanapt |
| Lundbeck LLC | $55.48 | 2025 | Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $38.94 | 2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.72 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $22.99 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $16.55 | 2025 | Rexulti |
| Organon LLC | $7.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.